Sun Pharma Advanced Research Company Limited — PPTs, 13-01-2026: Investor Presentation

SPARC's R&D Day highlighted a strategic pivot to focus on oncology and immunology, emphasizing modular platforms and partnerships to reduce clinical risk. Key programs like SCD-153 (topical for alopecia areata) and SBO-154 (MUC1 ADC for solid tumors) are progressing, with SCD-153's Phase 1B study initiated and SBO-154's Phase 1 dose escalation underway, both ahead of schedule.

Recent developments include a positive court ruling for a valuable Pediatric Rare Diseases Voucher (PRV), potentially exceeding $100 million. The SCO-155 small-molecule drug conjugate program is also advancing via a NewCo partnership with Tiller Therapeutics.

SPARC achieved significant operational streamlining, cutting annual fixed costs by $10 million and marginally reducing operational spend. Cumulative promoter-backed debt exceeds $45 million. Management aims to finalize a funding plan to extend cash runway to FY'28, with early efficacy data for SCD-153 expected by Q4 this year and SBO-154's maximum tolerated dose by Q3 2026. This repositioning aims to unlock future value.